NCT06660732

Rilonacept in Subjects With Cardiac Sarcoidosis

A RandomizEd PhAse II TrIal of Rilonacept in Subjects With Cardiac Sarcoidosis (REPAIR-CS)

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this study is to evaluate the effect of rilonacept, added to standard therapy and compared with standard therapy alone, on improvement in myocardial inflammation in subjects with cardiac sarcoidosis after 24 weeks of therapy.

Conditions

• Cardiac Sarcoidosis

Interventions

Type	Name	Description
DRUG	Rilonacept	320 mg subcutaneous (SC) loading dose delivered as two 2-mL, subcutaneous injections of 160 mg on the same day at different anatomical sites followed by once weekly 160 mg SC doses.

Timeline

• Start date: 2025-03-05
• Primary completion: 2026-11-01
• Completion: 2027-03-01
• First posted: 2024-10-28
• Last updated: 2025-08-15

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study